American Society for Radiation Oncology

American Society for Radiation Oncology
About Us
Quotes
Follow us:
Share:
Subscribe:

About Us

ASTRO is the premier radiation oncology society in the world, with more than 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals that specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, the Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes two medical journals, International Journal of Radiation Oncology • Biology • Physics (www.redjournal.org) and Practical Radiation Oncology (www.practicalradonc.org); developed and maintains an extensive patient website, www.rtanswers.org; and created the Radiation Oncology Institute (www.roinstitute.org), a non-profit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment. To learn more about ASTRO, visit www.astro.org.

Quotes

In the past, resistance mechanisms were usually thought of as static. Our study demonstrates, conversely, that a binary designation of resistance may oversimplify cancer’s true biology. These genetic mutations can fluctuate over time, and some patients can harbor more than one mutation.

Zofia Piotrowska, MD, lead author of the study

In an era where cancer treatment is increasingly personalized to the biology of each individual patient, our findings highlight the importance of molecular testing and the need for improved, noninvasive methods for serial testing.

Zofia Piotrowska, MD

In the past year, the Vice President’s moonshot initiative has brought critical attention to the need for greater collaboration and innovation in cancer research, and we are invigorated at the prospect of radiation oncology being an instrumental component of future progress. Moving forward, we must maintain the focus on advancing both the science and practice of cancer care while aligning our efforts to move Congress to authorize the $700 million requested by the President for cancer research initiatives. Substantial, predictable financial support is essential to sustain the fight to eradicate cancer.

Bruce G. Haffty, MD, FASTRO, past Chair of ASTRO’s Board of Directors

The goal of ASTRO’s 2016 Annual Meeting is to highlight the latest scientific and technological advances while emphasizing the importance of radiation oncology in providing value to cancer patients through cure and palliation.

ASTRO President David C. Beyer, MD, FASTRO

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Improved survival shown in early-stage Hodgkin’s Disease patients who receive radiation therapy

Mon, Sep 15, 2014 00:15 CET

Study included more than 41,000 patients across the U.S. from 1998 to 2011Patients with stage I and II Hodgkin’s Disease who receive consolidated radiation therapy (RT) have a higher 10-year survival rate of 84 percent, compared to 76 percent for patients who did not receive RT; and, the data also shows a decrease in utilization of RT, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 56th Annual Meeting. Researchers evaluated clinical features and survival outcomes among 41,502 patients diagnosed with stage I and II Hodgkin’s Disease from

There are no items matching the current filter

There are no more items matching the current filter

About Us

Links

Quotes

Improved survival shown in early-stage Hodgkin’s Disease patients who receive radiation therapy

Media

Share

About Us

Links

Quotes

Improved survival shown in early-stage Hodgkin’s Disease patients who receive radiation therapy

Media